Concordare Trials Secures $25 Million in Latest Funding Round

Concordare Trials secured $25 million in its latest funding round, adding another data point to the FinTech funding market.

Concordare Trials Raises $25 million in Funding

“Every day a trial runs late, a patient is waiting,” said Zach Sawaged, CEO and founder of Concordare Trials.

Investors Behind the Funding

The round was backed by Surface Ventures. Capvizr tracks this investor activity alongside sector momentum, co-investor patterns, and recent comparable raises.

Company Profile and Market Context

Concordare Trials operates in FinTech. Concordare Trials's financing adds to recent private-market activity.

Strategic Use of Funds

Accelerate Digitization of Clinical Trial Protocols.

Looking Ahead

Every day a trial runs late, a patient is waiting,

Source reference: original announcement/article.